We are live on ! Find out more
ABBV icon

AbbVie

3,794 hedge funds and large institutions have $239B invested in AbbVie in 2025 Q2 according to their latest regulatory filings, with 180 funds opening new positions, 1,712 increasing their positions, 1,472 reducing their positions, and 165 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $3.23B | Put options by funds: $2.09B

16% more repeat investments, than reductions

Existing positions increased: 1,712 | Existing positions reduced: 1,472

9% more first-time investments, than exits

New positions opened: 180 | Existing positions closed: 165

4% more capital inflows, than outflows

Capital inflows: $12.2B | Capital outflows: $11.7B

0.15% more ownership

Funds ownership: 72.83% → 72.98% (+0.15%)

1% less funds holding

Funds holding: 3,833 → 3,794 (-39)

39% less funds holding in top 10

Funds holding in top 10: 246 → 150 (-96)

Holders
3,794
Holders Change
-39
Holders Change %
-1.02%
% of All Funds
49.75%
Holding in Top 10
150
Holding in Top 10 Change
-96
Holding in Top 10 Change %
-39.02%
% of All Funds
1.97%
New
180
Increased
1,712
Reduced
1,472
Closed
165
Calls
$3.23B
Puts
$2.09B
Net Calls
+$1.14B
Net Calls Change
+$634M

ABBV Hedge Fund Activity: Q2 2025 in Review

3,794 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2025, worth a combined $239B — down 11% from $270B a quarter earlier.

Buyers outnumbered sellers: 180 funds opened new ABBV positions and 165 closed out — a net gain of 15 holders — while 1,712 added to existing stakes and 1,472 trimmed.

The largest buyer was Assenagon Asset Management, adding an estimated $681M. The largest seller was Capital World Investors, cutting an estimated $1.8B.

  • 3,794 institutional investors held AbbVie (ABBV) as of Q2 2025, down from 3,833 in Q1 2025.
  • Funds reported $239B of AbbVie stock for Q2 2025, down 11% quarter-over-quarter.
  • 180 funds opened new AbbVie positions in Q2 2025 and 165 closed out, a net change of +15 holders.
  • The largest AbbVie buyer in Q2 2025 was Assenagon Asset Management, an estimated $681M added.
  • The largest AbbVie seller in Q2 2025 was Capital World Investors, an estimated $1.8B sold.

Based on aggregated 13F filings for Q2 2025.